BiotechTV - News

CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.

CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.

Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.

He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.

Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.

Sponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory expertise, nimbleness, consulting and strategy skills, modeling and biostatistics knowhow, and more.

Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.

Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how companies have been trading, and their ability to raise money, off of data.

He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and carefully, and why he decided to launch City Therapeutics.

He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven.

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.